We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Biosearch and Seegene Finalize Oligonucleotide Supply and BHQ®, CAL Fluor® and Quasar® Licensing Agreements


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biosearch and Seegene Finalize Oligonucleotide Supply and BHQ®, CAL Fluor® and Quasar® Licensing Agreements"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
Biosearch Technologies, Inc., announces that the company has licensed access to the BHQ®, CAL Fluor® and Quasar® patents to Seegene. In addition, Biosearch will manufacture both research and IVD grade oligonucleotides for Seegene. Based in Seoul, Korea with a subsidiary in Rockville, Maryland, Seegene develops molecular diagnostic products based on PCR and real-time PCR technology.

Seegene’s Magicplex and Anyplex systems developed based on Seegene’s proprietary DPO and READ technologies are being sold in Human IVD, applied and research markets.

“Seegene’s multiplex PCR technology, combined with Biosearch’s BHQ, CAL Fluor, Quasar IP and oligo manufacturing expertise are a powerful and innovative solution in multiplex molecular diagnostics on real time PCR platforms” said Marc Beal, Director of Corporate Development at Biosearch Technologies. “We look forward to working with Seegene as they commercialize their current Seeplex, Magicplex and Anyplex product lines in Europe, Asia and the U.S.”

Dr. Sang-Kil Lee, Seegene’s Director of Business Development comments, “We are pleased to have a good partner in Biosearch Technologies, who can supply us sophisticated and high quality oligonucleotide components. We believe Seegene’s real time PCR products will offer both companies a whole new business opportunity in the global market, delivering a powerful multiplicity, sensitivity and specificity over a wide range of applications such as sepsis and MDR-TB.”
Advertisement